Immunotherapy-Chemo cocktail aims to shrink head and neck tumors before treatment

NCT ID NCT05758389

First seen Jun 26, 2026 ยท Last updated Jun 26, 2026

Summary

This study tests whether combining the immunotherapy drug tislelizumab with chemotherapy (paclitaxel, cisplatin, 5-FU) can shrink advanced head and neck tumors before surgery or chemoradiation. About 29 adults with stage III-IVb cancer will receive the combo for three cycles. Researchers will check tumor size and look for complete remission, while monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
tislelizumab (PD-1 inhibitor) combined with paclitaxel, cisplatin, and 5-FU chemotherapy
What this could lead to
If successful, this could offer a new treatment option for locally advanced head and neck cancer, potentially improving tumor shrinkage before surgery or chemoradiation.
What could go wrong
This is a small, early-phase trial with only 29 participants and no comparison group, so results may not apply broadly. Side effects from immunotherapy and chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Oncology, Drum Tower Hospital, Nanjing University School of Medicine

    RECRUITING

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.